Design, Synthesis and In Vitro Evaluation of Novel Anti-HIV 3-Pyrazol-3- yl-Pyridin-2-One Analogs

(E-pub Ahead of Print)

Author(s): Sanjay Kumar, Shiv Gupta, Shraddha Gaikwad, Leila Fotooh Abadi, Late Kamlesh Kumar Bhutani, Smita Kulkarni*, Inder Pal Singh*.

Journal Name: Medicinal Chemistry

Become EABM
Become Reviewer


Background: Natural products have shown potent anti-HIV activity, but some of these also possess toxicity. The pharmacophoric fragments of these natural products have scope of combination with other pharmacophoric fragment and derivatization to reduce toxicity and increase the potency. Combination of natural product fragments from different classes of anti–HIV compounds may lead to a new class of potent anti–HIV agents.

Objective: Design, in silico prediction of drug-likeness, ADMET properties and synthesis of pyrazol– pyridones. Evaluation of the anti–HIV1 activity of synthesized pyrazol–pyridones.

Method: Pyrazol–pyridones were designed by combining reported anti–HIV pharmacophoric fragments. Designed molecules were synthesized after in silico prediction of drug-likeness and ADMET properties. Compounds were evaluated for activity against HIV–1VB59 and HIV–1UG070.

Result: QED value of designed pyrazol–pyridones was greater than the known drug zidovudine. The designed compounds were predicted to be noncarcinogenic and nonmutagenic in nature. Seventeen novel pyrazol–pyridones were synthesized with good yield. Compound 6q and 6l showed activity with IC50 values 6.14 μM and 15.34 μM against HIV–1VB59 and 16.21 μM and 18.21 μM against HIV–1UG070, respectively.

Conclusion: Compound 6q was found to be most potent among the synthesized compounds with a therapeutic index of 54.31against HIV–1VB59. This is the first report of anti–HIV1 activity of pyrazol– pyridone class of compounds. Although the anti–HIV1 activity of these compounds is moderate, this study opens up a new class for exploration of chemical space for anti–HIV1 activity.

Keywords: Pyrazol–pyridone, Anti–HIV, Drug-likeness, QED, ADMET, HIV–1VB51, HIV–1UG070.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1573406414666181106125539
Price: $95